Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A

Melodia Therapeutics AG and Alivexis, Inc. have entered into an exclusive license agreement for the worldwide development, manufacturing, and commercialization of Alivexis' MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential. The agreement includes upfront payment and development and sales milestone payments totaling up to approximately $275 million (JPY 42.7 billion1), with additional royalties on net sales of any marketed product.